When uncontrolled, infectious inflammation compromises organ function and is associated with many widely occurring human diseases of major public health concern. Surgery, trauma, and tissue injury can enable invading organisms to cause infections and inflammation that, if unresolved, can be fatal. These barrier breaks and microbial invasion evoke acute inflammation that is ideally protective and self-resolving. Resolution of inflammation was believed to occur via passive dilution of chemical mediators and pro-inflammatory molecules. From this Program Project, evidence emerged indicating resolution is an active molecular process orchestrated by new families of specialized pro-resolving mediators (SPM). These structurally distinct families include resolvins (Rv), protectins (PD), maresins (MaR) and their newly discovered potent SPM-sulfido-conjugates (SC) that resolve inflammation and stimulate tissue regeneration (Conjugates in Tissue Regeneration; CTR). Our overall mission in this renewal is to systematically elucidate the structures and functions of nove mediators in resolution and tissue regeneration. Our strategic plan includes lipid mediator (LM)-SPM-metabolipidomics with resolution and regeneration indices to interrogate inflammatory exudates and tissues coupled with total organic synthesis of SPM and SPM-SC standards to validate structure-function. The overarching novel hypothesis to be addressed by each project of this renewal requires a highly multi-disciplinary team and approach. Together, we shall test the following: Infectious inflammatory exudates evoked by tissue injury, surgical trauma and infection emit potent soluble chemical mediators locally such as SPM and their newly identified sulfido- conjugates that actively orchestrate resolution of inflammation, enhance microbial killing and clearance, as well as tissue regeneration. These new molecular resolution programs are essential for host defense and dictate severity and recovery intervals. This program project team is configured to address these unmet challenges and consists of 3 highly interactive projects, 2 scientific cores and an administrative core with expert advisory panels focused on establishing lipid mediator-resolution functional metabolome, stereo-controlled synthesis of SPM, SPM-SC and their specific mechanisms in resolution of infectious inflammation and clearance pathways. Our broad goal is to harness these molecules and pathways to bring forth resolution pharmacology for new treatments to control infectious inflammation and related tissue damage.

Public Health Relevance

To improve patient care, a goal of this program project is to harness specialized pro- resolving mediators (SPMs) and their bioactive SPM-sulfido conjugates that we recently discovered for resolution pharmacology. This is a novel therapeutic approach to better treat human diseases and tissue injury where uncontrolled infectious inflammation and tissue regeneration are important. The potential for resolution pharmacology as a new therapeutic approach could diminish the healthcare consequences of uncontrolled prolonged infectious inflammation and tissue damage.

National Institute of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZGM1)
Program Officer
Okita, Richard T
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Brigham and Women's Hospital
United States
Zip Code
Norris, Paul C; Serhan, Charles N (2018) Metabololipidomic profiling of functional immunoresolvent clusters and eicosanoids in mammalian tissues. Biochem Biophys Res Commun 504:553-561
Werz, Oliver; Gerstmeier, Jana; Libreros, Stephania et al. (2018) Human macrophages differentially produce specific resolvin or leukotriene signals that depend on bacterial pathogenicity. Nat Commun 9:59
Colas, Romain A; Ashton, Anthony W; Mukherjee, Shankar et al. (2018) Trypanosoma cruzi Produces the Specialized Proresolving Mediators Resolvin D1, Resolvin D5, and Resolvin E2. Infect Immun 86:
Sham, Ho Pan; Walker, Katherine H; Abdulnour, Raja-Elie E et al. (2018) 15-epi-Lipoxin A4, Resolvin D2, and Resolvin D3 Induce NF-?B Regulators in Bacterial Pneumonia. J Immunol 200:2757-2766
Abdulnour, Raja-Elie E; Howrylak, Judie A; Tavares, Alexander H et al. (2018) Phospholipase D isoforms differentially regulate leukocyte responses to acute lung injury. J Leukoc Biol 103:919-932
Halade, Ganesh V; Kain, Vasundhara; Serhan, Charles N (2018) Immune responsive resolvin D1 programs myocardial infarction-induced cardiorenal syndrome in heart failure. FASEB J 32:3717-3729
Sorokin, Alexander V; Norris, Paul C; English, Justin T et al. (2018) Identification of proresolving and inflammatory lipid mediators in human psoriasis. J Clin Lipidol 12:1047-1060
Serhan, Charles N; Chiang, Nan; Dalli, Jesmond (2018) New pro-resolving n-3 mediators bridge resolution of infectious inflammation to tissue regeneration. Mol Aspects Med 64:1-17
Dalli, Jesmond; Colas, Romain A; Walker, Mary E et al. (2018) Lipid Mediator Metabolomics Via LC-MS/MS Profiling and Analysis. Methods Mol Biol 1730:59-72
Lahvic, Jamie L; Ammerman, Michelle; Li, Pulin et al. (2018) Specific oxylipins enhance vertebrate hematopoiesis via the receptor GPR132. Proc Natl Acad Sci U S A 115:9252-9257

Showing the most recent 10 out of 165 publications